$1.29-0.04 (-3.01%)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States.
NuCana plc in the Healthcare sector is trading at $1.29 with a market capitalization of $8M. The stock is currently near its 52-week low of $1.21, remaining 52.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$4.78Mβ | -$2.84Mβ | -$3.57Mβ | -$11.63Mβ | -$2.79M |
| Net Income | -$3.87Mβ | -$2.48Mβ | -$281,000β | -$24.11Mβ | -$2.47M |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs i...
European equities traded in the US as American depositary receipts started the week lower late Monda
European equities traded in the US as American depositary receipts were tracking modestly higher lat
European equities traded in the US as American depositary receipts were sharply higher late Thursday
European equities traded in the US as American depositary receipts were tracking sharply lower late
European equities traded in the US as American depositary receipts were trending higher late Monday